var title_f2_50_2848="Computer calculation of LV mass";
var content_f2_50_2848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Computer calculation of an estimate of left ventricular mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 144px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Only four simple measurements on the 2D echocardiogram&nbsp;are required&nbsp;for&nbsp;computer&nbsp;calculation of&nbsp;an estimate of left ventricular (LV) mass. The first two measurements are of the areas subtended by the epicardium and endocardium (A1 and A2), the third of the semimajor axis a, and the fourth, the truncated semimajor axis d.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2848=[""].join("\n");
var outline_f2_50_2848=null;
var title_f2_50_2849="Alogliptin and metformin: Drug information";
var content_f2_50_2849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alogliptin and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16057083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16057086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16057082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kazano&trade;: FDA approved January 2013; anticipated availability is the summer of 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16057088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise in patients not adequately controlled on alogliptin or metformin monotherapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87805 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2849=[""].join("\n");
var outline_f2_50_2849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057083\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057086\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057082\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057088\">",
"      Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_50_2850="Removal of etonogestrel contraceptive implant";
var content_f2_50_2850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Removal of etonogestrel contraceptive implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 645px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After sonographic localization of the implant, make a 3 mm incision transversely above the implant, open the modified vasectomy forceps over the implant, close the forceps around the implant, and then use the forceps to remove the implant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Speroff L, Darney PD. A Clinical Guide for Contraception, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2850=[""].join("\n");
var outline_f2_50_2850=null;
var title_f2_50_2851="Should I have a screening test for Down syndrome during pregnancy?";
var content_f2_50_2851=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/50/2851/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2851/contributors\" id=\"au441\">",
"       Jacquelyn V Halliday, MS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2851/contributors\" id=\"au5125\">",
"       Geralyn M Messerlian, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2851/contributors\" id=\"au4915\">",
"       Jacob A Canick, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/50/2851/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2851/contributors\" id=\"se6173\">",
"       Louise Wilkins-Haug, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/50/2851/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2851/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/50/2851?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     This topic provides information about prenatal screening for Down syndrome to help you decide if you want to undergo this test.",
"    </p>",
"    <p>",
"     More detailed information about Down syndrome screening tests is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"      \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS DOWN SYNDROME?",
"     </span>",
"    </p>",
"    <p>",
"     The first decision you need to make is if you want to know, before it is born, whether your developing baby has Down syndrome. It may help to review some facts about the condition. More detailed information is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=see_link\">",
"      \"Patient information: Down syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Down syndrome is caused by an extra number 21 chromosome",
"      </li>",
"      <li>",
"       It occurs in about 1 in 700 births",
"      </li>",
"      <li>",
"       People with Down syndrome have mild to moderate intellectual disability (mental retardation), meaning that the person can often do things independently; however, most need supervision throughout their lives.",
"      </li>",
"      <li>",
"       People with Down syndrome have characteristic facial features (",
"       <a class=\"graphic graphic_picture graphicRef67446 \" href=\"UTD.htm?33/56/34690\">",
"        picture 1",
"       </a>",
"       ), meaning that their facial features are similar to those of other people with Down syndrome",
"      </li>",
"      <li>",
"       People with Down syndrome may have birth defects, such as problems with how the heart or intestines develop. Other medical problems can also develop.",
"      </li>",
"      <li>",
"       The average lifespan for an individual with Down syndrome is about 50 to 60 years",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Could my baby have Down syndrome?",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A woman of any age can have a baby with Down syndrome, but the chance gets higher as a woman gets older.",
"      </li>",
"      <li>",
"       Down syndrome usually does not run in families, except in rare cases. You should inform your doctor or nurse if you or your partner has a family member with Down syndrome.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHAT INFORMATION DOES A PRENATAL SCREENING TEST FOR DOWN SYNDROME PROVIDE?",
"     </span>",
"    </p>",
"    <p>",
"     A screening test will tell you the chances of having a certain medical condition.",
"    </p>",
"    <p>",
"     Screening tests for Down syndrome cannot tell for certain whether your baby actually has Down syndrome; rather, they tell you whether there is a low or high risk that the baby is affected. By comparison, a diagnostic test can tell for certain if the baby has Down syndrome.",
"    </p>",
"    <p>",
"     The advantage of Down syndrome screening tests is that they only require a blood test from the mother, and possibly an ultrasound, so there is no risk to the pregnancy. The diagnostic tests for Down syndrome require putting a needle into the uterus or placenta and removing some fluid or tissue. There is a small risk of miscarriage after a diagnostic test.",
"    </p>",
"    <p>",
"     The decision to have a prenatal screening test for Down syndrome is yours and depends upon your wishes, values, and beliefs. There is no right or wrong choice; you decide what is best for you and your family.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      WHO IS OFFERED A SCREENING TEST FOR DOWN SYNDROME?",
"     </span>",
"    </p>",
"    <p>",
"     The American College of Obstetricians and Gynecologists recommends that",
"     <strong>",
"      all",
"     </strong>",
"     pregnant women, regardless of age, be offered the opportunity to have a screening test for Down syndrome before 20 weeks of pregnancy. Screening tests for Down syndrome are voluntary, meaning that it is your choice whether to have or not have these tests.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      DECIDING TO HAVE A SCREENING TEST FOR DOWN SYNDROME",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Why should I have a screening test?",
"     </span>",
"     &nbsp;&mdash;&nbsp;These are some of the reasons that women choose to have screening for Down syndrome:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       I want as much information as possible during pregnancy about the health of my developing baby.",
"      </li>",
"      <li>",
"       If my baby has Down syndrome, I want to know while I am pregnant so I can learn as much as possible about the condition before the baby is born.",
"      </li>",
"      <li>",
"       I am planning to deliver my baby in a community hospital, so if my baby has serious birth defects associated with Down syndrome (eg, heart or intestinal abnormalities), I would rather deliver at a hospital with a special care nursery.",
"      </li>",
"      <li>",
"       I have been anxious since I learned I was pregnant and if I find out that my baby's risk of having Down syndrome is low, I believe it will help ease my anxiety.",
"      </li>",
"      <li>",
"       I want to consider all of my options. If my developing baby has Down syndrome, I would want the option to terminate the pregnancy.",
"      </li>",
"      <li>",
"       I am not sure what I would do, or how I would feel, if my baby has Down syndrome. I am going to take it one step at a time. If my screening test comes back saying I am at increased risk, I will decide at that time if I want to have more testing.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Why might I choose not to have a screening test?",
"     </span>",
"     &nbsp;&mdash;&nbsp;These are some of the reasons that a woman might choose NOT to have screening:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       I have decided that \"whatever will be, will be,\" and I will wait until the baby's birth to find out if the baby is healthy.",
"      </li>",
"      <li>",
"       I do not want to be faced with decisions about my unborn baby. Because of religious or personal beliefs, I would never consider terminating an affected pregnancy.",
"      </li>",
"      <li>",
"       Since I know I would never have a diagnostic test, even with only a small risk of a miscarriage, I do not want to have a screening test.",
"      </li>",
"      <li>",
"       I want to know for sure if the developing baby has Down syndrome, so I am having a diagnostic test (eg, chorionic villus sampling [CVS] or amniocentesis) rather than a screening test. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=see_link\">",
"        \"Patient information: Chorionic villus sampling (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"        \"Patient information: Amniocentesis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Some common myths about screening for Down syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the reasons women decide whether or not to have screening are based on incorrect information, such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Myth &mdash; My baby won't have Down syndrome because I am young, I exercise, and I am healthy.",
"      </li>",
"      <li>",
"       Fact &mdash; A woman of any age can have a baby with Down syndrome, regardless of her health.",
"      </li>",
"      <li>",
"       Myth &mdash; My baby won't have Down syndrome because I do not drink or smoke.",
"      </li>",
"      <li>",
"       Fact &mdash; Avoiding alcohol or tobacco during pregnancy is very important for the health of you and your baby; however, it does",
"       <strong>",
"        not",
"       </strong>",
"       affect the chance that your baby will have Down syndrome.",
"      </li>",
"      <li>",
"       Myth &mdash; My baby won't have Down syndrome because no one in my family or the father of the baby's family has Down syndrome.",
"      </li>",
"      <li>",
"       Fact &mdash; Down syndrome usually does not run in families. Your baby can be affected even if there is no one else in the family with Down syndrome. If you have a family history of Down syndrome, you should talk to your doctor, nurse, or a genetic counselor to discuss if it will increase your risk of having a baby with Down syndrome.",
"      </li>",
"      <li>",
"       Myth &mdash; I should not have screening for Down syndrome unless I know that I would terminate the pregnancy if Down syndrome were detected.",
"      </li>",
"      <li>",
"       Fact &mdash; Many people who would not terminate their pregnancy choose to have screening. These people want information about their unborn baby's health before birth to plan for delivery and newborn care.",
"      </li>",
"      <li>",
"       Myth &mdash; My friend told me that if I have a screening test, it will come back \"positive\" since most people who have the test end up with a \"positive\" result.",
"      </li>",
"      <li>",
"       Fact &mdash; Most people who have a screening test will have a \"negative\" result, meaning that the baby has a low risk of having Down syndrome.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHAT DOWN SYNDROME SCREENING TESTS ARE AVAILABLE?",
"     </span>",
"    </p>",
"    <p>",
"     There are several different screening tests available. Some important considerations include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       How far along in pregnancy are you?",
"      </li>",
"      <li>",
"       What screening tests are available in your area?",
"      </li>",
"      <li>",
"       What, if any, diagnostic tests (chorionic villus sampling [CVS] or amniocentesis) are available in your area?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There are four basic types of screening tests for Down syndrome. Some of these tests need to be done early in the pregnancy, while one is not done until 15 to 18 weeks of pregnancy (at around 4 months).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       First-trimester screening is done during the first trimester (typically at 11 to 13 weeks of pregnancy). The test involves a test of your blood and an ultrasound of the developing baby.",
"      </li>",
"      <li>",
"       Second-trimester screening is done during the second trimester (typically at 15 to 18 weeks of pregnancy). The test only requires a sample of your blood.",
"      </li>",
"      <li>",
"       Integrated testing combines results from tests done during the first and second trimesters. These tests involve two samples of your blood, and often include an ultrasound of the developing baby. Results are usually available in the second trimester. In some variations of this test, called sequential screening or contingent screening, results are available earlier if you are at very high or very low risk of having a baby with Down syndrome.",
"      </li>",
"      <li>",
"       A newest screening method is the measurement of free DNA in maternal plasma, which can be done beginning at 10 weeks of gestation.&nbsp;This test only requires a sample of your blood. It is only done in women at high risk of having a Down syndrome pregnancy and can markedly reduce the need for invasive diagnostic testing (amniocentesis, CVS). It may not be paid for by your health insurance.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Which screening test should I choose?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The \"best\" screening test depends upon your values and preferences. You can use the following statements to help guide your decision (",
"     <a class=\"graphic graphic_table graphicRef66116 \" href=\"UTD.htm?40/46/41707\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TEST RESULTS",
"     </span>",
"    </p>",
"    <p>",
"     Your risk of having a baby with Down syndrome is based on your age and the results of the blood test and ultrasound measurement. It takes about one week to get results.",
"    </p>",
"    <p>",
"     For most tests, the results will be given as a number. As an example, a woman with a result of 1 in 2000 would have a low risk that the baby is affected. A woman with a result of 1 in 100 would be considered at high risk that the baby is affected.",
"    </p>",
"    <p>",
"     There is no screening result that will tell for sure if the developing baby definitely does or does not have Down syndrome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Screen positive results",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your test shows an increased risk of having a baby with Down syndrome, you can choose to have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Further (diagnostic) testing, if you want to know for sure if your baby is affected. It will take about 2 to 3 weeks to schedule, perform, and get the results back from a diagnostic test.",
"      </li>",
"      <li>",
"       No further testing during pregnancy. If needed, the infant can be tested after birth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     To help you with your decision, consider meeting with a genetic counselor. He or she can help you balance the risks and benefits of diagnostic testing. Talking with a counselor can also help you think about the issues involved in ending a pregnancy or raising a child with Down syndrome.",
"    </p>",
"    <p>",
"     Two diagnostic tests are available:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Chorionic villus sampling (CVS) &mdash; CVS is the test that would be done if you were in the first trimester of pregnancy. The test is performed between 10 and 13 weeks of pregnancy and has a small risk of miscarriage (about 1 miscarriage for every 100 procedures). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=see_link\">",
"        \"Patient information: Chorionic villus sampling (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Amniocentesis &mdash; Amniocentesis is the test that would be done if you were in your second trimester (after 14 weeks of pregnancy). Amniocentesis is thought to have a smaller risk of miscarriage (less than 1 miscarriage for every 200 procedures) compared with CVS. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"        \"Patient information: Amniocentesis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193582\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193589\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/50/11043?source=see_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=see_link\">",
"      Patient information: Down syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193597\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=see_link\">",
"      Patient information: Down syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=see_link\">",
"      Patient information: Chorionic villus sampling (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193605\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"      Second trimester maternal serum screening for Down syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=see_link\">",
"      Laboratory issues related to maternal serum screening for Down syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/50/2851/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/50/2851?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2851/abstract/1\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2851/abstract/2\">",
"      Ball RH, Caughey AB, Malone FD, et al. First- and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol 2007; 110:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2851/abstract/3\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007; 110:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2851/abstract/4\">",
"      Berkowitz RL, Cuckle HS, Wapner R, D'Alton ME. Aneuploidy screening: what test should I use? Obstet Gynecol 2006; 107:715.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_50_2851=[""].join("\n");
var outline_f2_50_2851=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS DOWN SYNDROME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHAT INFORMATION DOES A PRENATAL SCREENING TEST FOR DOWN SYNDROME PROVIDE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           WHO IS OFFERED A SCREENING TEST FOR DOWN SYNDROME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           DECIDING TO HAVE A SCREENING TEST FOR DOWN SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHAT DOWN SYNDROME SCREENING TESTS ARE AVAILABLE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TEST RESULTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/56/34690\" title=\"picture 1\">",
"           Child Down syndrome PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?40/46/41707\" title=\"table 1\">",
"           Down syndrome screening PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_50_2852="Anatomy for central neck dissection";
var content_f2_50_2852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Anatomy for central neck dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 585px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2852=[""].join("\n");
var outline_f2_50_2852=null;
var title_f2_50_2853="Trendelenburg gait";
var content_f2_50_2853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Trendelenburg gait in a boy with SCFE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) When stepping on the unaffected side, the pelvis remains level. B) When stepping on the affected side, the pelvis tilts downward toward the unaffected side, and there is a subtle shift of the torso.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2853=[""].join("\n");
var outline_f2_50_2853=null;
var title_f2_50_2854="PML after organ transplantation";
var content_f2_50_2854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Brain MRI of progressive multifocal leukoencephalopathy after cardiac transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted (A) and FLAIR (B) images show hyperintensity in a confluent bifrontal pattern. Pre-contrast T1- weighted image (C) shows hypointensity in the lesion. Post-contrast T1-weighted image (D) demonstrates enhancement along the periphery, or advancing edge, of this lesion, suggesting a region of more active disease. The diffusion-weighted image (E) shows hyperintensity along this leading edge. The corresponding ADC map (F) shows diffuse increase in signal intensity suggesting facilitated water diffusion; however, there have been reports of restricted diffusion at the periphery (see text).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2854=[""].join("\n");
var outline_f2_50_2854=null;
var title_f2_50_2855="Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases";
var content_f2_50_2855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2855/contributors\">",
"     Philip Seo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2855/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2855/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2855/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2855/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/50/2855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF), a powerful inhibitor of lymphocyte proliferation, has been used since the early 1990s for the prevention of acute allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/1\">",
"     1",
"    </a>",
"    ].MMF has subsequently gained popularity as a potential glucocorticoid-sparing agent for the treatment of patients with a variety of rheumatic illnesses. However, with the notable exception of use in systemic lupus erythematous, it has not been studied in large randomized clinical trials.",
"   </p>",
"   <p>",
"    The pharmacology of MMF and the side effects associated with its use are discussed in this topic review. The use of MMF in specific autoimmune disorders, in organ transplantation, and in other conditions with presumed immunologic bases (eg, Crohn&rsquo;s disease) is presented separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMF has an oral bioavailability of 94 percent. The drug is rapidly hydrolyzed after absorption to mycophenolic acid, its active metabolite. The plasma concentration of mycophenolic acid peaks 0.8 hours after administration and has secondary peaks from enterohepatic recirculation. MMF itself is undetectable 10 minutes after absorption, but the half-life of mycophenolic acid is 11.6 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only free mycophenolic acid is believed to be pharmacologically active [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/3\">",
"     3",
"    </a>",
"    ]. In general, 97 percent of mycophenolic acid is bound to albumin. This percentage is decreased in the setting of hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/4\">",
"     4",
"    </a>",
"    ]. Levels of free mycophenolic acid, therefore, may be increased in patients with hepatic dysfunction or hypoalbuminemia.",
"   </p>",
"   <p>",
"    More than 90 percent of mycophenolic acid is metabolized by glucuronidation to 7-O-glucuronide, an inactive compound that is excreted in the urine and feces [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/5\">",
"     5",
"    </a>",
"    ]. It is uncertain whether MMF dose adjustments are necessary in patients with liver dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/6\">",
"     6",
"    </a>",
"    ]. Measurement of free and total mycophenolic acid in the serum as a guide to dose adjustment has been advocated by some investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] but is not a common practice.",
"   </p>",
"   <p>",
"    Dose adjustments are necessary in the setting of severe chronic renal failure. Renal failure prolongs the half-life of the glucuronide (but not of mycophenolic acid itself), and accumulation of the glucuronide metabolite may account for increased gastrointestinal upset when MMF is used in patients on peritoneal- or hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of an enteric-coated formulation of MMF (Myfortic&reg;) results in delayed absorption but slightly better bioavailability; a dose of 720 mg is therapeutically equivalent to 1000 mg of plain MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated lymphocytes are dependent upon the de novo synthesis of purine nucleotides. The conversion of inosine monophosphate to guanosine monophosphate is catalyzed by inosine monophosphate (IMP) dehydrogenase. Mycophenolic acid reversibly inhibits IMP dehydrogenase, leading to decreased B- and T-cell proliferation and to decreased antibody production. MMF may lead to immunosuppression through other mechanisms, as well, including the induction of apoptosis of activated T lymphocytes and the inhibition of adhesion molecule expression and lymphocyte recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two properties of mycophenolic acid explain the relatively specific inhibition of lymphocyte proliferation. First, IMP dehydrogenase catalyzes the rate-limiting step in purine nucleotide synthesis in lymphocytes but not in other cell types. Second, mycophenolic acid preferentially binds the type II isoform of IMP dehydrogenase, which is expressed by activated lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With appropriate patient selection and monitoring, the side effect profile of MMF is generally at least as good as those of most immunomodulatory agents used in rheumatic disease. MMF is clearly safer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    in most circumstances. Thiopurine methyltransferase deficiency, an important potential concern when prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    ), is not an issue with MMF. Gastrointestinal symptoms and leukopenia are the most commonly observed adverse effects, but these usually resolve with dose adjustments.",
"   </p>",
"   <p>",
"    Despite its favorable side effect profile, MMF does have certain potential downsides in rheumatic disease treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For many conditions, rigorous studies attesting to the efficacy of MMF do not exist.",
"     </li>",
"     <li>",
"      MMF is substantially more expensive than other drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) that may have equal or greater efficacy depending upon the disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of 85 patients receiving MMF for the treatment of psoriasis, nearly 75 percent initially had gastrointestinal (GI) symptoms, including nausea, diarrhea, and abdominal cramping [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/13\">",
"     13",
"    </a>",
"    ]. These symptoms were tolerated better with time and rarely required cessation of the drug. After several years of therapy, the prevalence of GI symptoms had declined to approximately 20 percent, and the symptoms were minor in these patients.",
"   </p>",
"   <p>",
"    GI side effects are also frequent in patients being treated for SLE and are responsible for drug discontinuation in up to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/14\">",
"     14",
"    </a>",
"    ]. Daily doses as low as 125 mg may cause intolerable symptoms. In some patients, complaints improve with more frequent dosing intervals (maintaining the same total daily dose). Other patients may require reductions in the total dose. Enteric-coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    sodium is another option for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathologic changes associated with GI symptoms have not been characterized in rheumatic disease patients treated with MMF but have been studied in a retrospective series of solid organ transplant recipients, who had undergone diagnostic colonic biopsies for such symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/16\">",
"     16",
"    </a>",
"    ]. Abnormal findings were observed in 69 percent of 32 patients with GI symptoms on MMF (500 to 1000 mg twice daily), including changes suggestive of inflammatory bowel disease (28 percent), of graft-versus-host disease (19 percent), of ischemia (3 percent), or of self-limited colitis (16 percent). In comparison, only one of eight patients not on MMF had significant changes, a mild graft-versus-host disease-like pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone marrow suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytopenias are major potential concerns and require regular monitoring. Complete blood counts should be performed after the first one to two weeks of therapy and then once every six to eight weeks thereafter if no cytopenia is noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMF is listed as a category D drug by the US Food and Drug Administration (FDA) in pregnancy due to increases both in first trimester pregnancy loss and in congenital malformations, including cleft lip and palate, as well as anomalies of the distal limbs, heart, esophagus, and kidneys (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H18#H18\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large studies examining the incidence of infections in patients with rheumatic illness treated with MMF. The existing studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/17\">",
"     17",
"    </a>",
"    ] are too small to permit generalizations. There are, however, large numbers of patients with solid organ transplants who have been treated with MMF. Studying these patients has led to the following observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pneumocystis jirovecii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is somewhat counterintuitive, there is some reason to believe that MMF exerts a protective effect against Pneumocystis jirovecii. In animal models, MMF demonstrates an antimicrobial effect against this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/18\">",
"     18",
"    </a>",
"    ]. Moreover, in four randomized, controlled trials of MMF in renal allograft transplant recipients, none of the 1068 patients who received MMF (compared with 10 of the 563 patients who did not) developed P. jirovecii infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of heart transplant recipients, a higher incidence of herpes zoster was associated with MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/20\">",
"     20",
"    </a>",
"    ]. Of greater concern, however, is the risk of cytomegalovirus (CMV) infection. A higher incidence of tissue-invasive CMV infections has been documented in clinical trials of renal allograft recipients who received MMF as part of their immunosuppression regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This same increase in incidence of tissue-invasive CMV infections has not been observed in trials of patients treated with MMF who have received liver, heart, or lung transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with rheumatic illness treated with MMF are presumably at risk for developing the same opportunistic infections seen in patients with solid organ transplants. These patient populations, however, may not be directly comparable. Patients with SLE, for example, are inherently more susceptible to infection than the general population. This may be due to a number of factors, including defects in chemotaxis, impaired phagocytosis, decreased immune complex clearance, abnormal complement levels, and mutations in mannose-binding lectin and Fc receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/26\">",
"     26",
"    </a>",
"    ]. Moreover, previous exposure to cytotoxic agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) may have a prolonged effect on the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/27\">",
"     27",
"    </a>",
"    ]. Even after the white blood cells in the peripheral circulation return to normal levels, there may be a delay in recovery of functional CD4 T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/28\">",
"     28",
"    </a>",
"    ]. These factors may make patients with rheumatic illnesses susceptible to a spectrum of opportunistic infections that is different from that of solid organ transplant patients treated with MMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive immunosuppressive agents are at increased risk of developing malignant neoplasms, including lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H10#H10\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Is cancer risk increased?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the patients who develop lymphoid malignancies, many are taking a combination of immunosuppressive agents, and, therefore, the risk attributable to a single agent is uncertain. However, one reported case of central nervous system lymphoma that occurred during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    monotherapy for myasthenia gravis suggests that MMF use alone may confer an increased risk of lymphoid neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/29\">",
"     29",
"    </a>",
"    ]. MMF prescribing information includes a specific warning about lymphoma and other neoplasms as a result of immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aluminum and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    antacids, iron supplements, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine resin",
"    </a>",
"    decrease absorption of MMF. Chronic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    leads to potentially clinically significant decreases (as much as twofold) in serum levels of mycophenolic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/30\">",
"     30",
"    </a>",
"    ]. This may be due to simultaneous induction of renal, hepatic, and gastrointestinal uridine diphosphate-glucuronosyltransferases and organic anion transporters with subsequent functional inhibition of enterohepatic recirculation of mycophenolic acid.",
"   </p>",
"   <p>",
"    Other drug-drug interactions involving MMF are uncommon. Other than the interaction between MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    noted above, no interactions have been reported between MMF and beta-lactam antibiotics, glycopeptides, macrolides, aminoglycosides, quinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , or azole antifungal agents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMF may decrease the efficacy of other medications, such as oral contraceptives. The toxicity of MMF may be enhanced by other medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    (which may increase serum levels of mycophenolic acid) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (which also induces bone marrow suppression). Coadministration of these agents should be avoided when possible. In the case of oral contraceptives, a second form of contraception should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DRUG DOSE AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target dose of MMF for the treatment of rheumatic diseases is generally between 1.5 and 3 grams daily, in divided doses. Most patients will tolerate MMF if the daily dose is taken twice daily. The maximum dose of MMF in patients with chronic renal failure (ie, a glomerular filtration rate less than 25",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    should not exceed 2 grams daily. Patients with end-stage renal disease, already at risk for anemia because of erythropoietin deficiency, must be monitored closely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2855/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Starting with lower doses at first (eg, 500 mg daily for several days) may improve a patient&rsquo;s gastrointestinal tolerance of MMF. After several days, the dose of MMF may be rapidly increased to the target dose.",
"   </p>",
"   <p>",
"    A complete blood count should be performed one to two weeks after the start of therapy. If there is no evidence of bone marrow suppression at that time, it is our practice to check complete blood counts every six to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil (MMF) has good oral bioavailability and is rapidly hydrolyzed after absorption to mycophenolic acid, its active metabolite. Mycophenolic acid is highly bound to albumin. The proportion bound is decreased with hyperbilirubinemia, and levels of free mycophenolic acid may be increased in patients with hepatic dysfunction or hypoalbuminemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 90 percent of mycophenolic acid is metabolized to 7-O-glucuronide, an inactive compound that is excreted in the urine and feces. Dose adjustments are necessary in the setting of severe chronic renal failure, which prolongs the half-life of the glucuronide but not of mycophenolic acid itself. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mycophenolic acid acts by reversibly inhibiting inosine monophosphate (IMP) dehydrogenase, leading to decreased B- and T-cell proliferation and yo decreased antibody production, which is due to the dependence of activated lymphocytes upon de novo synthesis of purine nucleotides. MMF may lead to immunosuppression through other mechanisms as well. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms and leukopenia are the most commonly observed adverse effects of MMF, but these usually resolve with dose adjustments. Complete blood counts should be performed after the first one to two weeks of therapy and then once every six to eight weeks thereafter if no cytopenia is noted. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Gastrointestinal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Bone marrow suppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increased risk of first trimester pregnancy loss, of congenital malformations, and of other anomalies have led to MMF being listed as a category D drug by the FDA in pregnancy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H18#H18\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Mycophenolate mofetil'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risks of infection, lymphoma, and other neoplasms may be increased with use of MMF, but adequate data to assess such risk in patients with rheumatic disease are not available. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Neoplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several drug interactions may affect the absorption of MMF or the levels of mycophenolic acid, and MMF may decrease the efficacy of oral contraceptives. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/1\">",
"      Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/2\">",
"      Lipsky JJ. Mycophenolate mofetil. Lancet 1996; 348:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/3\">",
"      Shaw LM, Korecka M, Aradhye S, et al. Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant Proc 1998; 30:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/4\">",
"      Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/5\">",
"      Mackenzie PI. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 2000; 22:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/6\">",
"      Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996; 36:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/7\">",
"      DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/8\">",
"      Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am J Transplant 2004; 4:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/9\">",
"      MacPhee IA, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000; 57:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/10\">",
"      Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003; 37:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/11\">",
"      Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/12\">",
"      McMurray RW, Harisdangkul V. Mycophenolate mofetil: selective T cell inhibition. Am J Med Sci 2002; 323:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/13\">",
"      Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/14\">",
"      Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/15\">",
"      Massari P, Duro-Garcia V, Gir&oacute;n F, et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005; 37:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/16\">",
"      Selbst MK, Ahrens WA, Robert ME, et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol 2009; 22:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/17\">",
"      Kingdon EJ, McLean AG, Psimenou E, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/18\">",
"      Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/19\">",
"      Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/20\">",
"      Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/21\">",
"      A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/22\">",
"      Sarmiento JM, Dockrell DH, Schwab TR, et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/23\">",
"      Renlund DG, Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/24\">",
"      Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/25\">",
"      Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001; 71:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/26\">",
"      Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002; 16:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/27\">",
"      Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985; 55:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/28\">",
"      Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/29\">",
"      Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005; 65:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/30\">",
"      Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 2005; 78:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2855/abstract/31\">",
"      Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57:421.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7990 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2855=[""].join("\n");
var outline_f2_50_2855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone marrow suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pneumocystis jirovecii",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DRUG DOSE AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_50_2856="Role of echocardiography in atrial fibrillation";
var content_f2_50_2856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of echocardiography in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2856/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2856/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2856/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/50/2856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of echocardiographic imaging among patients with atrial fibrillation (AF) can be divided into several categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of cardiac chamber sizes and function, the pericardium, and valvular function. This information may be helpful in determining the conditions associated with AF, and risk for recurrent AF following cardioversion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identification of patients at increased risk for thromboembolic complications of AF before cardioversion and in patients with chronic AF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"       \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"       \"Risk of embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nearly all patients presenting with their",
"    <strong>",
"     first episode",
"    </strong>",
"    of AF will benefit from transthoracic (surface) echocardiographic (TTE) evaluation of left atrial size, left ventricular systolic function, and mitral valve morphology and function. A more selected subgroup may benefit from the additional information obtained from transesophageal echocardiographic (TEE) evaluation for left atrial thrombi and for guidance concerning early cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies from the Stroke Prevention in Atrial Fibrillation (SPAF) investigators confirmed the usefulness of transesophageal echocardiography (TEE) for predicting thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This study involved 786 patients with nonrheumatic AF, 382 of whom were at high clinical risk for a thromboembolism (eg, women &gt;75 years of age and patients with systolic blood pressure &gt;160 mmHg or a history of previous thromboembolism, impaired left ventricular function, or recent congestive heart failure). The rate of stroke was increased over threefold when dense spontaneous echo contrast was present, threefold by reduced left atrial appendage peak flow velocity and left atrial appendage thrombus, and fourfold by complex aortic plaque.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSTHORACIC ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTE provides detailed information about cardiac anatomy and function. In comparison, it is less useful for the detection of thrombus in the left atrium or left atrial appendage, which is better detected by TEE. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Left atrial thrombi'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Left atrial size",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTE is particularly helpful in assessing left atrial size in AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31528?source=see_link\">",
"     \"Echocardiographic evaluation of the atria and appendages\"",
"    </a>",
"    .) The normal left atrial dimension in adults is less than 4.0 cm (or &lt;2.0",
"    <span class=\"nowrap\">",
"     cm/m2",
"    </span>",
"    body surface area). Left atrial enlargement is common in AF, particularly in patients with mitral valve disease, left ventricular dilation, annular calcification, or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, sustained AF itself can lead to a further increase in left atrial size [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/4\">",
"     4",
"    </a>",
"    ], an effect that is reversible after cardioversion and maintenance of sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/5\">",
"     5",
"    </a>",
"    ]. Pulsed Doppler studies have shown that the time to recovery of atrial mechanical function is directly related to the duration of AF (eg, within 24 hours in patients with AF for &le;2 weeks and up to one month in those with AF for more than six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the routine clinical role of this technique is uncertain.",
"   </p>",
"   <p>",
"    Regardless of the mechanism, left atrial enlargement is important prognostically. It decreases the probability that long-term maintenance of sinus rhythm will be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Patients with chronic (more than one year) AF, rheumatic mitral valve disease, and severe left atrial enlargement (greater than 6.0 cm) are at greatest risk for recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/9\">",
"     9",
"    </a>",
"    ]. If, however, the duration of AF is brief, an attempt at cardioversion is reasonable for most patients regardless of absolute left atrial size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although TTE can provide anatomic imaging of the body of the left atrium, TEE is preferred when looking for left atrial thrombi and assessing left atrial appendage and right atrial appendage anatomy and function (abnormalities of which predispose to the thrombus formation). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Transesophageal echocardiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitral valve function",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTE is quite useful in the assessment of mitral valve function, which can influence the risk of thrombus formation. As an example, occult mitral stenosis in the adult may initially present with AF, often in the setting of acute thromboembolism. In this setting, long-term anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is indicated even if cardioversion to sinus rhythm is successful. Long-term maintenance of sinus rhythm is unlikely unless the mitral stenosis is corrected (by surgery or percutaneous balloon mitral valvuloplasty). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mitral regurgitation is commonly found among patients with AF. Its effect on thrombus formation varies with the duration of AF. Moderate to severe mitral regurgitation appears to",
"    <strong>",
"     protect",
"    </strong>",
"    against clinical thromboembolism in chronic AF, presumably by minimized stasis in the left atrium and atrial appendage and less coagulation activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43528?source=see_link\">",
"     \"Mechanisms of thrombogenesis in atrial fibrillation\"",
"    </a>",
"    .) However, it does not appear to protect from atrial appendage thrombus on TEE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Left ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTE assessment of left ventricular systolic function helps to guide the choice of pharmacologic therapy for ventricular rate control in chronic AF.",
"   </p>",
"   <p>",
"    A beta blocker or a calcium channel blocker (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) is recommended for patients with preserved left ventricular systolic function, while patients with depressed left ventricular systolic function may be best treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . Patients with overt heart failure due to systolic dysfunction are often treated with both a beta blocker to improve survival and digoxin to control symptoms, independent of the presence or absence of AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TTE can also detect left ventricular hypertrophy, focal wall motion abnormalities suggestive of myocardial infarction, and conditions less frequently associated with AF, including pericarditis (pericardial effusion), pulmonary embolus (dilated and poorly functioning right ventricle), and aortic stenosis (AF is generally poorly tolerated in this disorder and does not occur until very late in the disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link&amp;anchor=H17#H17\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Left ventricular dysfunction, as determined from the TTE, independently predicts an increased risk of a stroke in patients with AF. Analysis of 1066 patients entered into three prospective clinical trials evaluating the role of anticoagulation in nonvalvular AF (BAATAF, SPINAF, and SPAF) found that, among patients in the placebo or control groups, the incidence of a stroke was 9.3 percent per year in patients with moderate to severe left ventricular dysfunction compared to 4.4 percent per year in those with normal or mildly abnormal left ventricular systolic function (",
"    <a class=\"graphic graphic_figure graphicRef70244 \" href=\"UTD.htm?13/51/14141\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/14\">",
"     14",
"    </a>",
"    ]. The predictive value of left ventricular dysfunction for thromboembolic risk has been confirmed in many other studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'Risk models'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRANSESOPHAGEAL ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations provide the rationale for the performance of TTE in all patients presenting with their first episode of AF. On the other hand, TEE should be reserved for patients in whom the diagnostic information will lead to alterations in therapy. It is a moderately invasive imaging technique that provides superior visualization of posterior structures, such as the left atrium and left atrial appendage.",
"   </p>",
"   <p>",
"    TEE has particular value in estimating thromboembolic risk in different clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can detect left atrial thrombi as a guide to early cardioversion. In this setting, there is little additional benefit from TTE prior to TEE, as most of the necessary information can be derived from the TEE with its superior assessment of the appendages. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"       \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients in paroxysmal or chronic AF, abnormalities in the left atrial appendage (thrombus, dense spontaneous echo contrast, or flow velocity &le;20",
"      <span class=\"nowrap\">",
"       cm/s)",
"      </span>",
"      or the presence of a complex aortic plaque increases the risk of a thromboembolic event and are more likely in patients with clinical risk factors for thromboembolism (",
"      <a class=\"graphic graphic_figure graphicRef55452 \" href=\"UTD.htm?4/8/4239\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Left atrial thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;A main advantage of TEE is that it provides superior visualization of posterior structures, such as the left atrium and left atrial appendage. This is particularly important for the detection on thrombi at these sites.",
"   </p>",
"   <p>",
"    The ability of TTE to identify or exclude left atrial or atrial appendage thrombi is limited, with a reported sensitivity of 39 to 63 percent, due largely to poor visualization of the left atrial appendage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In contrast, TEE permits detection of thrombus in both the left atrium (",
"    <a class=\"graphic graphic_movie graphicRef51472 \" href=\"UTD.htm?10/61/11231\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64234 \" href=\"UTD.htm?30/38/31343\">",
"     movie 2",
"    </a>",
"    ) and the left atrial appendage (",
"    <a class=\"graphic graphic_movie graphicRef56080 \" href=\"UTD.htm?23/51/24383\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66795 \" href=\"UTD.htm?4/61/5072\">",
"     movie 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    TEE evidence of left atrial thrombi is seen in approximately 13 percent of patients presenting with nonrheumatic AF of more than three days duration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The prevalence is increased in high-risk patients with mitral stenosis (33 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/20\">",
"     20",
"    </a>",
"    ], left ventricular systolic dysfunction, enlargement of the left atrium or left atrial appendage, spontaneous echo contrast, or a recent thromboembolic event (43 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/21\">",
"     21",
"    </a>",
"    ]. Recurrent embolization in the last setting may be due to migration of the residual thrombus. On the other hand, the apparent lack of atrial thrombi in 57 percent of these patients probably reflects migration of the entire thrombus during the embolic event, a thrombus not visualized by TEE due to its small size, or another source for the embolus.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of TEE for left atrial thrombi (in patients in whom the left atrium was directly examined at surgery) are 93 to 100 percent and 99 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In a review of 231 patients in whom only 5.2 percent had a left atrial thrombus, TEE has a positive and negative predictive value of 86 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One potential limitation of these studies is that they were performed by experienced operators and the accuracy may not be replicable at all institutions. Multiplane TEE imaging enables visualization of the body of the left atrium and left atrial appendage from multiple imaging planes, thereby providing superior assessment. It is the current standard approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .) The complementary role of three-dimension real-time TEE is unknown.",
"   </p>",
"   <p>",
"    Cardioversion should",
"    <strong>",
"     not",
"    </strong>",
"    be attempted in patients with TEE evidence for atrial thrombi, even if thrombi appear &ldquo;adherent&rdquo; to the wall of the appendage. Such patients are typically given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy for four weeks before cardioversion as are patients who do not undergo TEE. Resolution of thrombi occurs in approximately 75 percent of patients with nonrheumatic AF within this four week period, with no formation of new thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There does not appear to be a role for routine TEE prior to cardioversion in patients who have been adequately anticoagulated (INR 2 to 3) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the time of resolution is more prolonged in patients with rheumatic mitral valve disease; in such patients, repeat TEE is recommended to document thrombus resolution prior to cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One setting in which the value of TEE is uncertain is in acute AF of less than 48 hours duration. Historically, these patients have been considered to be at low risk for clinical thromboembolism associated with cardioversion unless they have other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This hypothesis has been confirmed in more recent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This was illustrated in a report of 375 consecutive patients with AF of less than 48 hours duration in whom screening TEE was not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/27\">",
"     27",
"    </a>",
"    ]. Conversion to sinus rhythm during the hospitalization occurred in 95 percent of patients; a clinical thromboembolic event occurred in three (0.8 percent), each of whom converted spontaneously. This overall rate of clinical thromboembolism is similar to what would have been expected with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy for one month prior to cardioversion.",
"   </p>",
"   <p>",
"    Based upon these observations, we do not perform TEE or delay cardioversion for those with a history of AF of less than 48 hours (or greater than 48 hours, but therapeutically anticoagulated within 48 hours of AF onset), unless there is coexisting rheumatic mitral valve disease, severe left ventricular systolic dysfunction, or a history of thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spontaneous echo contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous echo contrast (SEC or \"smoke\") refers to the presence of dynamic, smoke-like echoes seen during TEE in the left atrium or atrial appendage (",
"    <a class=\"graphic graphic_movie graphicRef51472 \" href=\"UTD.htm?10/61/11231\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66795 \" href=\"UTD.htm?4/61/5072\">",
"     movie 4",
"    </a>",
"    ). Although most widely studied in the left atrium, SEC also occurs in the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/17,29\">",
"     17,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Right atrial thrombi'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SEC is thought to reflect increased erythrocyte aggregation caused by low shear rate due to altered atrial flow dynamics and uncoordinated atrial systole [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Erythrocyte aggregation is mediated by plasma proteins, especially fibrinogen, which promotes red cell rouleaux formation by moderating the normal electrostatic forces (due to negatively charged membranes) which keep erythrocytes from aggregating [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SEC is a strong risk factor for and may be the preceding stage to thrombus formation and thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1,2,33,34\">",
"     1,2,33,34",
"    </a>",
"    ]. The following clinical characteristics of SEC have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SEC is present in over 50 percent of all patients with AF and in over 80 percent of those with left atrial appendage thrombi or a recent thromboembolic event [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1,2,14,21,29,33,34\">",
"       1,2,14,21,29,33,34",
"      </a>",
"      ]. Furthermore, serial TEE studies have shown that SEC subsequently develops in many patients with AF (44 percent in one report) who do not have SEC on initial TEE [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The left atrial appendage peak outflow velocity can be estimated by TEE and SEC semiquantitatively graded as marked or dense if present throughout the entire cardiac cycle, or faint when intermittent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1,33\">",
"       1,33",
"      </a>",
"      ]. The risk of thromboembolism increases as these parameters worsen [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SEC is associated with clinical risk factors for thromboembolism, including a prior thromboembolic event, left ventricular systolic dysfunction, and hypertension (",
"      <a class=\"graphic graphic_figure graphicRef55452 \" href=\"UTD.htm?4/8/4239\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1\">",
"       1",
"      </a>",
"      ]. On the other hand, it is less common in patients with mitral regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/33\">",
"       33",
"      </a>",
"      ] which, as noted above, appears to protect against clinical thromboembolism in chronic AF, presumably by minimized stasis in the left atrium and atrial appendage [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/10-13\">",
"       10-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      , which leads to thrombus resolution and a lower incidence of thromboembolism, does not affect the presence of SEC, since it does not change the underlying hemodynamic abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/32,34,35\">",
"       32,34,35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blood flow velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to estimate blood flow velocity in the left or right atrium and left and right atrial appendage permits a more quantifiable measure of stasis. A low appendage blood flow velocity is associated with the presence of appendage thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/29,33,36\">",
"     29,33,36",
"    </a>",
"    ] and with denser SEC [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. The risk of stroke increases sharply with marked reductions in blood flow velocity (&lt;15",
"    <span class=\"nowrap\">",
"     cm/sec),",
"    </span>",
"    particularly in the left atrial appendage or posterior left atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that left atrial blood flow velocity also may be a predictor of the likelihood of maintaining sinus rhythm after cardioversion. In one report, a high peak left atrial appendage blood flow velocity (&gt;40",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    identified patients with an increased likelihood of remaining in sinus rhythm one year after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/38\">",
"     38",
"    </a>",
"    ]. In comparison, low blood velocity was of limited predictive value. Other reports have been conflicting on the predictive value of low left atrial appendage blood flow velocity for the maintenance of sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Right atrial thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer data are available comparing the sensitivity, specificity, and accuracy of TTE and TEE for right atrial and right atrial appendage thrombi, but the right atrial appendage is rarely seen by TTE. In contrast right atrial or atrial appendage thrombi are also easily seen by TEE (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68756 \" href=\"UTD.htm?27/59/28607\">",
"     image 1",
"    </a>",
"    ). They are much less common than left atrial thrombi in patients in AF, occurring in 3 to 6 percent of cases (versus 15 to 20 percent for left atrial thrombi) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/17,29\">",
"     17,29",
"    </a>",
"    ]. The majority of patients with right atrial thrombi also have left atrial thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/14\">",
"     14",
"    </a>",
"    ]. Cardioversion should be deferred even if patients have isolated right atrial thrombi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine performance of transthoracic echocardiography is suggested for all patients presenting with their first episode of atrial fibrillation (AF) to obtain information regarding atrial size, ventricular function, possible pericardial effusion, and valvular function. Repeated transthoracic echocardiographic examinations for recurrent AF are not necessary unless the clinical presentation has changed.",
"   </p>",
"   <p>",
"    The main advantage of transesophageal echocardiography (TEE) is its ability to detect left and right atrial thrombi and patients at risk for thrombi because of the presence of spontaneous echo contrast or reduced left atrial appendage blood flow velocity. The main clinical use of TEE is in the management of anticoagulation in patients with AF of more than 48 hours or high-risk patients with AF of shorter duration who are candidates for cardioversion. Standard therapy in such patients consists of four weeks of therapeutic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy before cardioversion, which will cause resolution of most thrombi in patients with nonrheumatic AF with a low likelihood for formation of new thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/23\">",
"     23",
"    </a>",
"    ]. An alternative approach is TEE-guided therapy (without initial transthoracic echocardiography). Cardioversion can be performed with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    if no thrombi are seen; this is followed by a month of warfarin therapy to prevent new thrombus formation after cardioversion (",
"    <a class=\"graphic graphic_table graphicRef72971 graphicRef54077 \" href=\"UTD.htm?4/54/4973\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72676 \" href=\"UTD.htm?3/30/3565\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/19,41\">",
"     19,41",
"    </a>",
"    ]. On the other hand, cardioversion should be",
"    <strong>",
"     delayed",
"    </strong>",
"    if thrombi are seen in any cardiac chamber [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There does not appear to be a role for routine TEE prior to cardioversion in patients who have been adequately anticoagulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least four weeks prior to cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2856/abstract/24\">",
"     24",
"    </a>",
"    ]. However, TEE immediately prior to elective cardioversion should be considered for those patients at increased risk for left atrial thrombi (eg, rheumatic mitral valve disease,",
"    <span class=\"nowrap\">",
"     recent/prior",
"    </span>",
"    thromboembolism, severe left ventricular systolic dysfunction). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Transesophageal echocardiography'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/1\">",
"      Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/2\">",
"      Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/3\">",
"      Dittrich HC, Pearce LA, Asinger RW, et al. Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators. Am Heart J 1999; 137:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/4\">",
"      Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990; 82:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/5\">",
"      Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989; 13:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/6\">",
"      Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/7\">",
"      H&ouml;glund C, Rosenhamer G. Echocardiographic left atrial dimension as a predictor of maintaining sinus rhythm after conversion of atrial fibrillation. Acta Med Scand 1985; 217:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/8\">",
"      Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/9\">",
"      Brodsky MA, Allen BJ, Capparelli EV, et al. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989; 63:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/10\">",
"      Blackshear JL, Pearce LA, Asinger RW, et al. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol 1993; 72:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/11\">",
"      Ozkan M, Kaymaz C, Kirma C, et al. Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement. Am J Cardiol 1998; 82:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/12\">",
"      Nakagami H, Yamamoto K, Ikeda U, et al. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J 1998; 136:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/13\">",
"      Goldsmith IR, Blann AD, Patel RL, Lip GY. Reduced indexes of left atrial hypercoagulability in patients with severe mitral regurgitation. Am J Cardiol 2000; 86:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/14\">",
"      Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/15\">",
"      Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995; 123:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/16\">",
"      Hwang JJ, Chen JJ, Lin SC, et al. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol 1993; 72:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/17\">",
"      Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/18\">",
"      Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001; 110:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/19\">",
"      Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/20\">",
"      Srimannarayana J, Varma RS, Satheesh S, et al. Prevalence of left atrial thrombus in rheumatic mitral stenosis with atrial fibrillation and its response to anticoagulation: a transesophageal echocardiographic study. Indian Heart J 2003; 55:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/21\">",
"      Manning WJ, Silverman DI, Waksmonski CA, et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 1995; 155:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/22\">",
"      Tardif JC, Schwartz SL, Vannan MA, et al. Clinical usefulness of multiplane transesophageal echocardiography: comparison to biplanar imaging. Am Heart J 1994; 128:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/23\">",
"      Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995; 92:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/24\">",
"      Seidl K, Rameken M, Dr&ouml;gem&uuml;ller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol 2002; 39:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/25\">",
"      Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 1989; 95:118S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/26\">",
"      Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992; 326:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/27\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/28\">",
"      Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/29\">",
"      de Divitiis M, Omran H, Rabahieh R, et al. Right atrial appendage thrombosis in atrial fibrillation: its frequency and its clinical predictors. Am J Cardiol 1999; 84:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/30\">",
"      Black IW, Chesterman CN, Hopkins AP, et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/31\">",
"      Fatkin D, Herbert E, Feneley MP. Hematologic correlates of spontaneous echo contrast in patients with atrial fibrillation and implications for thromboembolic risk. Am J Cardiol 1994; 73:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/32\">",
"      Fatkin D, Loupas T, Low J, Feneley M. Inhibition of red cell aggregation prevents spontaneous echocardiographic contrast formation in human blood. Circulation 1997; 96:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/33\">",
"      Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/34\">",
"      Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/35\">",
"      Tsai LM, Chen JH, Lin LJ, Teng JK. Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation. Am J Cardiol 1997; 80:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/36\">",
"      Santiago D, Warshofsky M, Li Mandri G, et al. Left atrial appendage function and thrombus formation in atrial fibrillation-flutter: a transesophageal echocardiographic study. J Am Coll Cardiol 1994; 24:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/37\">",
"      Shively BK, Gelgand EA, Crawford MH. Regional left atrial stasis during atrial fibrillation and flutter: determinants and relation to stroke. J Am Coll Cardiol 1996; 27:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/38\">",
"      Antonielli E, Pizzuti A, P&aacute;link&aacute;s A, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2002; 39:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/39\">",
"      Verhorst PM, Kamp O, Welling RC, et al. Transesophageal echocardiographic predictors for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. Am J Cardiol 1997; 79:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/40\">",
"      P&eacute;rez Y, Duval AM, Carville C, et al. Is left atrial appendage flow a predictor for outcome of cardioversion of nonvalvular atrial fibrillation? A transthroacic and transesophageal echocardiographic study. Am Heart J 1997; 134:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/41\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123:e269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2856/abstract/42\">",
"      Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37:691.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 908 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2856=[""].join("\n");
var outline_f2_50_2856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSTHORACIC ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Left atrial size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitral valve function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Left ventricular function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRANSESOPHAGEAL ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Left atrial thrombi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blood flow velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Right atrial thrombi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/908|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/59/28607\" title=\"diagnostic image 1\">",
"      Apical 4 chamber echo right atrial thrombus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/908|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/51/14141\" title=\"figure 1\">",
"      LV function stroke risk in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/8/4239\" title=\"figure 2\">",
"      TEE abnormalities stroke risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/908|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/61/11231\" title=\"movie 1\">",
"      TEE LA thrombus and spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/38/31343\" title=\"movie 2\">",
"      TEE LA and prosthetic MV thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/51/24383\" title=\"movie 3\">",
"      TEE LA appendage thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?4/61/5072\" title=\"movie 4\">",
"      TEE left atrial appendage thrombus and spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/0/32779\" title=\"table 1A\">",
"      Conventional approach to cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/35/2620\" title=\"table 1B\">",
"      TEE approach to cardioversion of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/30/3565\" title=\"table 2\">",
"      ACC AHA ESC anticoag cardiovert",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31528?source=related_link\">",
"      Echocardiographic evaluation of the atria and appendages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43528?source=related_link\">",
"      Mechanisms of thrombogenesis in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=related_link\">",
"      Surgical management of mitral stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_50_2857="First trimester cystic hygroma and increased nuchal translucency";
var content_f2_50_2857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First trimester cystic hygroma and increased nuchal translucency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Lynn L Simpson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/50/2857/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/50/2857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal ultrasound screening in early pregnancy involves an assessment of the nuchal region of the fetus. Although a small hypoechoic space in the posterior fetal neck is a normal finding in all first trimester fetuses, excessive enlargement is associated with an increased risk of Down syndrome, as well as other fetal abnormalities. Excessive enlargement may be related to a cystic hygroma or to mesenchymal edema (termed increased nuchal translucency).",
"   </p>",
"   <p>",
"    The diagnosis and clinical significance of first trimester cystic hygroma and increased nuchal translucency will be reviewed here. A detailed discussion of first trimester screening for Down syndrome and other aneuploidies is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOGENESIS OF NUCHAL ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cystic hygroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic hygroma is a congenital malformation of the lymphatic system in which obstruction between the lymphatic and venous pathways in the fetal neck leads to lymph accumulation in the jugular lymphatic sacs of the nuchal region. Cystic hygromas can be subclassified as septated or nonseptated (simple). In the first trimester, the overall prevalence of septated and nonseptated cystic hygromas is about 1 in 100 fetuses, and the prevalence of septated cystic hygromas is 1 in 285 fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nuchal translucency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuchal translucency is the hypoechoic region located between the skin and soft tissues behind the cervical spine. This hypoechoic space is presumed to represent mesenchymal edema and is often associated with distended jugular lymphatics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A small, but measurable, amount of nuchal fluid can be identified in virtually all fetuses between the 10th and 14th week of gestation, and is considered a normal finding if below a defined threshold (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Prenatal diagnosis'",
"    </a>",
"    below). On the other hand, an increased nuchal translucency is associated with a wide range of abnormalities, which suggests that there are different pathophysiologic pathways that lead to the common end-point of increased nuchal fluid. Possible etiologies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered dermal collagen composition (eg, Down syndrome)",
"     </li>",
"     <li>",
"      Abnormal nuchal lymphogenesis (eg, Turner syndrome)",
"     </li>",
"     <li>",
"      Hemodynamic alterations and cardiac dysfunction (eg, heart defects)",
"     </li>",
"     <li>",
"      Abnormal endothelial cell differentiation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased nuchal translucency is often associated with aneuploidy, particularly trisomy 21 and Turner syndrome (monosomy X) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The pathophysiology is different for the two aneuploidies. In trisomy 21, the collagen content of the dermis is abnormal; its hydrophilic properties may lead to the accumulation of subcutaneous fluid. By comparison, fetuses with Turner syndrome often have lymphatic dysplasia. These fetuses are also at risk for narrowing of the aortic isthmus and widening of the ascending aorta, which may lead to overperfusion of the head and neck, thus contributing to the development of subcutaneous edema. Nuchal translucency may regress if these connections are established later in gestation.",
"   </p>",
"   <p>",
"    Increased nuchal translucency can be concurrent with distended jugular lymphatic sacs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/3\">",
"     3",
"    </a>",
"    ]. Abnormal lymphatic development in the fetal neck could lead to distension of the jugular venous sacs, an accumulation of fluid in the nuchal region, and retrograde increases in venous pressure. This hypothesis is supported by the observation that reversed or absent ductus venosus flow during atrial contraction is observed in these fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/7\">",
"     7",
"    </a>",
"    ]. Eventual recanalization or formation of collaterals may explain the transient nature of abnormal ductus venosus waveforms and nuchal edema.",
"   </p>",
"   <p>",
"    Increased nuchal translucency is also an important marker for congenital heart disease. Although nuchal edema in fetuses with heart defects had initially been thought to be related to impaired atrial contraction, reduced myocardial compliance, or cardiac failure, studies have not supported these mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. No differences in intracardiac flow velocities in normal fetuses and fetuses with increased nuchal translucency have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/9\">",
"     9",
"    </a>",
"    ]. Changes in the carotid artery, jugular vein, or ductus venosus Doppler velocimetry are also not significantly related to nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/10\">",
"     10",
"    </a>",
"    ]. Pericardial, pleural, and peritoneal fluid (ascites) are frequent findings in fetuses with cardiac decompensation, but are rare in fetuses with increased nuchal translucency.",
"   </p>",
"   <p>",
"    The most common heart anomalies found in fetuses with increased nuchal translucency are septal defects, which are rarely associated with in utero cardiac failure. In fact, the type of cardiac defect cannot always explain the hemodynamic changes found in fetuses with increased nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, there does not seem to be any significant difference in the type of heart malformation in fetuses with and without increased nuchal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although no clear pathophysiologic mechanism adequately explains increased nuchal translucency in cases of congenital heart disease, aberrant endothelial development may be the link between abnormalities of the lymphatic and cardiovascular systems. Disturbances in endothelial differentiation could contribute to increases in nuchal fluid, abnormal ductus venosus waveforms, and congenital heart anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal nuchal fluid collections are classified as to type (cystic hygroma versus increased nuchal translucency), size, simple versus septated, and associated findings (eg, hydrops fetalis, congenital anomalies).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal time to assess the nuchal fluid is at 11 weeks of gestation, but measurements can be obtained at fetal crown-rump lengths of 36 to 84 mm, which correspond to approximately 10 to 14 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis of cystic hygroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic hygromas consist of large single or multilocular fluid-filled cavities, which are usually easily identified during first trimester ultrasound examination. They tend to be largest in the nuchal region, but may extend along the entire length of the fetus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76486 \" href=\"UTD.htm?6/44/6851\">",
"     image 1",
"    </a>",
"    ). Multiple internal septae or trabeculae may be detected when imaging a cystic hygroma in multiple planes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61492 \" href=\"UTD.htm?0/15/244\">",
"     image 2",
"    </a>",
"    ). On transverse imaging of the fetal neck, a simple cystic hygroma may contain a single midline septum that makes it appear biseptate. In both simple (nonseptate or biseptate) and septated cystic hygromas, the distended jugular lymph sacs can sometimes be visualized on either side of the fetal neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis of nuchal translucency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique for measuring nuchal translucency is well defined and involves measuring the nuchal fluid space from its inner-to-inner borders in the midsagittal plane. The widest area of lucency should be measured. Care must be taken to identify the amnion since it may be separate from the chorion until 16 weeks of gestation and thus may be mistakenly identified as the posterior aspect of the fetal skin (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62637 \" href=\"UTD.htm?4/11/4274\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54043 graphicRef77700 \" href=\"UTD.htm?19/16/19718\">",
"     image 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Different thresholds have been used to classify nuchal translucency as abnormal. The most commonly used cut-offs are the 95th and 99th percentiles for gestational age, given that nuchal translucency normally increases with gestational age. Although the cut-offs in millimeters vary from 10 to 14 weeks, in high-risk populations the 99th percentile has been observed to remain quite constant at a measurement of 3.5 millimeters, independent of gestational age or crown-rump length [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate measurement of nuchal translucency is affected by several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/12\">",
"     12",
"    </a>",
"    ]. There is a significant learning period for performing accurate nuchal translucency measurement in the first trimester. In two large multicenter studies of first trimester Down syndrome screening, accurate nuchal translucency measurement required stringent training, formalized evaluation of sonographers' competence, and continuing external quality control [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In the latter trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/14\">",
"     14",
"    </a>",
"    ], adequate nuchal translucency images could not be obtained in 6 percent of cases. Fetal position and maternal body habitus may also affect the ability to obtain an accurate measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another issue is that nuchal translucency measurements vary from week to week, and abnormal nuchal measurements can quickly revert to normal, even in fetuses with Down syndrome. Therefore, when an abnormal measurement is obtained, we counsel the patient according to that measurement and do not revise counseling if a subsequent measurement is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cystic hygroma or nuchal thickening?",
"    </span>",
"    &nbsp;&mdash;&nbsp;With improvements in first trimester imaging, the distinction between simple cystic hygroma and increased nuchal translucency has become less clear. In fact, it has been suggested that septations can be observed in all nuchal fluid collections and therefore, cannot be used to distinguish between nuchal translucency and cystic hygroma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/16\">",
"     16",
"    </a>",
"    ]. In both cases, a single central septum may be identified on transverse imaging and may represent the normal midline ligamentum nuchae. The question then becomes: is a biseptate nuchal fluid collection a simple cystic hygroma or increased nuchal translucency? Possible distinguishing features of cystic hygromas are that they tend to be larger, extend along the entire length of the fetus, and are more likely to contain multiple septae, whereas nuchal translucency is often confined to the nuchal region between the occiput and upper spine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2\">",
"     2",
"    </a>",
"    ]. Regardless of the etiology, size appears to be the significant determinant of outcome for all nuchal fluid collections, irrespective of whether there are internal septations or the fluid envelops the entire length of the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other defects in the differential diagnosis of cystic hygroma include neural tube defects, such as a posterior encephalocele, or cervical meningocele, and cystic teratoma or hemangioma. These diagnoses can usually be excluded on high resolution transvaginal ultrasonography if an intact skull and spine are visualized, no solid component is seen in the cystic space, color-flow mapping shows a limited vascular supply, and internal septae are identified in the cystic mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35560?source=see_link\">",
"     \"Ultrasound diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ASSOCIATED ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Aneuploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic hygromas and increased nuchal translucency are associated with fetal aneuploidy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cystic hygroma",
"      </strong>",
"      &mdash; First trimester cystic hygromas are often associated with trisomies, whereas second trimester cystic hygromas are often associated with monosomy X [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/6\">",
"       6",
"      </a>",
"      ]. About 50 percent of first trimester septated cystic hygromas occur in fetuses with chromosomal abnormalities, most commonly trisomy 21 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2,17\">",
"       2,17",
"      </a>",
"      ]. Chromosomal abnormalities appear to be more frequent in septated cystic hygromas than in nonseptated cystic hygromas (incidence of abnormalities 57 versus 21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/18\">",
"       18",
"      </a>",
"      ], although these findings have not been consistent across studies. As an example, one study of simple first trimester cystic hygromas measuring &ge;2 millimeters reported 60 percent were associated with abnormal karyotypes, with trisomy 21 occurring in one-fourth of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/19\">",
"       19",
"      </a>",
"      ]. The lack of a standard definition of cystic hygroma and differences in adjustment for size likely contribute to disparate published results.",
"      <br/>",
"     </li>",
"     <li>",
"      <strong>",
"       Increased nuchal translucency",
"      </strong>",
"      &mdash; Similar to first trimester cystic hygromas, increased nuchal translucency is most often associated with trisomy 21 (Down syndrome). Trisomy 13 (Patau syndrome), trisomy 18 (Edward syndrome), monosomy X (Turner syndrome), and triploidy are also found with increased frequency among fetuses with increased nuchal translucency [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The risk of aneuploidy increases with increasing nuchal translucency thickness; the proportion of fetuses with aneuploidy will depend upon the threshold utilized. The following findings were noted in two large series:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study, among fetuses with a nuchal translucency at &ge;95th percentile, 12 percent had chromosomal abnormalities and 72 percent of trisomy 21 cases were identified in this subset of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the other study, the incidence of aneuploidy by nuchal thickness measurement was: from the 95th percentile for crown-rump length up to 3.4 mm (7 percent), 3.5 to 4.4 mm (20 percent), 5.5 to 6.4 mm (50 percent), and &ge;8.5 mm (75 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/21\">",
"       21",
"      </a>",
"      ]. Approximately 50 percent of fetuses with increased nuchal translucency and an abnormal karyotype had trisomy 21; the rest had other chromosomal abnormalities. Most fetuses with trisomy 21 had a nuchal thickness less than 4.5 mm. By comparison, most fetuses with trisomy 13, trisomy 18, and Turner syndrome had nuchal thickness &ge;4.5 mm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Structural anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-third of euploid fetuses with first trimester septated cystic hygromas have major structural anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. In contrast, structural anomalies are detected in only 4 to 10 percent of euploid fetuses with increased nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Associated malformations include cardiac defects, diaphragmatic hernia, renal anomalies, body stalk disruption, and abdominal wall defects. In one review, 2 to 8 percent of the malformations were undiagnosed before birth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac defects are the most common malformation associated with increased nuchal translucency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link&amp;anchor=H7#H7\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\", section on 'Nuchal translucency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link&amp;anchor=H11#H11\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\", section on 'Fetal risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of congenital heart disease increases with increasing nuchal translucency thickness, but there is no clear difference in the distribution of nuchal translucency with different types of cardiac defects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Depending upon the cut-off used, the overall risk of having a cardiac defect in an euploid fetus with increased nuchal translucency is about 3 to 5 percent (the baseline risk of moderate and severe forms of congenital heart disease in the general population is 6 per 1000 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a wide spectrum of cardiac malformations are observed, septal defects are the most common in fetuses with increased nuchal translucency. Increased nuchal translucency with fetal bradycardia suggests the presence of complex congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/30\">",
"     30",
"    </a>",
"    ]. Congenital heart block identified very early in gestation can be associated with cardiosplenic syndromes, also known as heterotaxy.",
"   </p>",
"   <p>",
"    Normal ductus venosus waveforms demonstrate forward flow during atrial contraction, or a positive A-wave. When atrial contraction occurs against increased impedance, a higher proportion of blood is ejected backwards into the great veins and the ductus venosus, resulting in an absent or reversed A-wave [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/31\">",
"     31",
"    </a>",
"    ]. Abnormal ductus venosus velocities are more common in fetuses with both increased nuchal translucency and cardiac defects than in fetuses with increased nuchal translucency alone. Both decreased mean velocities during late diastole and an increased pulsatility index of the ductus venosus have been reported in fetuses with nuchal translucency &ge;95th percentile and cardiac defects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, reversed or absent A-wave in the ductus venosus in the first trimester has been associated with a three-fold increase in the likelihood of a major heart defect, and the finding of normal ductus venosus flow reduces the risk by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/32\">",
"     32",
"    </a>",
"    ]. In euploid fetuses with increased nuchal translucency, a systematic review found that the sensitivity and specificity of an abnormal ductus venosus waveform for detecting congenital heart disease were 83 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While first trimester Doppler assessment of the ductus venosus in fetuses with increased nuchal translucency may help to identify those most at risk for congenital heart disease, it does not perform well enough to exclude fetal echocardiography in the midtrimester. For this reason, first trimester Doppler velocimetry should be reserved for at risk fetuses and the duration of interrogation should be as short as possible to limit fetal exposure to Doppler.",
"   </p>",
"   <p>",
"    Along with increased nuchal translucency and ductus venosus reversed A-wave, fetal tricuspid regurgitation is another finding associated with congenital heart disease in euploid first trimester fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/34\">",
"     34",
"    </a>",
"    ]. It has been reported to be present in about 35 percent of fetuses with cardiac defects versus 1 percent of fetuses without cardiac defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Twin-to-twin transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chromosomally normal twin pregnancies, the prevalence of nuchal translucency &gt;95th percentile is higher in monochorionic twins than in dichorionic twins (8.4 versus 5.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/35\">",
"     35",
"    </a>",
"    ]. In these cases, the increased nuchal translucency identifies a subset of monochorionic twins at increased risk of twin-to-twin transfusion syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant discordance between nuchal translucency measurements in monochorionic twins is also predictive of twin-to-twin transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. About 25 percent of monochorionic twins will have an intertwin discordance in nuchal translucency measurement of &gt;20 percent; this subset of twins is more likely to develop twin-to-twin transfusion syndrome and experience early fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Multiple gestation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In large screening studies, neurodevelopmental delay and genetic syndromes accounted for 0.5 to 6.5 percent of pregnancies with increased nuchal thickness and euploid chromosome complement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/39\">",
"     39",
"    </a>",
"    ]. A specific gene(s) has not been identified for over half of these developmental and genetic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/40\">",
"     40",
"    </a>",
"    ]. Of the syndromes known to be associated with a specific gene(s), more than three quarters have defined pathological mutations, which may be identified by prenatal molecular testing.",
"   </p>",
"   <p>",
"    Over 100 different",
"    <span class=\"nowrap\">",
"     developmental/genetic",
"    </span>",
"    syndromes have been associated with increased nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. In addition to the common aneuploidies discussed above, Noonan syndrome, multiple pterygium syndrome, Roberts syndrome, Cornelia de Lange syndrome, congenital adrenal hyperplasia, spinal muscular atrophy, DiGeorge syndrome, Smith-Lemli-Opitz syndrome, and a variety of skeletal dysplasias have been diagnosed in these children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2,40\">",
"     2,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical outcomes associated with cystic hygroma and increased nuchal translucency are markedly different (",
"    <a class=\"graphic graphic_table graphicRef76817 \" href=\"UTD.htm?29/17/29979\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. However, for both entities, increasing size is associated with increasing risk of abnormal outcome (eg, aneuploidy, major anomaly, perinatal death) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/20,21,43\">",
"     20,21,43",
"    </a>",
"    ] and the presence of a large or persistent nuchal fluid accumulations is a poor prognostic factor, even in euploid non-anomalous fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cystic hygroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pediatric outcomes occur in 15 to 30 percent of fetuses with first trimester cystic hygromas, but the prognosis for a specific fetus depends upon the presence or absence of associated findings. As discussed above, 50 percent of fetuses with cystic hygroma have an abnormal karyotype and another 33 percent have a structural anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2\">",
"     2",
"    </a>",
"    ]. The outcome of these cases depends upon the specific chromosomal or structural anomaly.",
"   </p>",
"   <p>",
"    In the absence of aneuploidy or structural anomalies, the size of the first trimester cystic hygroma appears to be the most important determinant of outcome. The prognosis is less favorable with a large cystic hygroma compared with a small cystic hygroma or increased nuchal translucency.",
"   </p>",
"   <p>",
"    While size appears to be of clinical significance, there is no clear correlation between septations and outcome, which may reflect the lack of standard definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/16\">",
"     16",
"    </a>",
"    ]. In one prospective study, close to 80 percent of septated first trimester cystic hygromas resolved between 15 and 30 weeks of gestation; however, only 17 percent of these fetuses had a normal pediatric outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 80 percent of simple cystic hygromas with normal karyotype are expected to resolve within four weeks of diagnosis and the vast majority of these patients deliver phenotypically normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the presence of hydrops associated with a cystic hygroma carries close to an 80 percent risk of poor outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nuchal translucency",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, increased first trimester nuchal translucency is associated with a 15 percent risk of aneuploidy overall, as well as an increased risk of structural abnormalities. Nuchal translucency commonly resolves spontaneously; those that do not resolve by the second trimester have a higher likelihood of chromosomal abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of 11 studies including 2128 euploid fetuses with increased nuchal translucency (&ge;3 mm or 95th percentile) reported the following frequency of outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal outcome (70 to 90 percent)",
"     </li>",
"     <li>",
"      Miscarriage (2.2 to 10.6 percent)",
"     </li>",
"     <li>",
"      Perinatal death (0.5 to 15.8 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of nuchal translucency thickness and presence of additional anomalies are predictive of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/22,28,41,45,46\">",
"     22,28,41,45,46",
"    </a>",
"    ]. First trimester nuchal translucency of 3.5 to 4.4 mm is associated with a normal outcome in 70 percent of fetuses, whereas nuchal translucency of 5.5 to 6.4 mm is associated with a normal outcome in only 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two series, the overall frequency of adverse outcome (eg, miscarriage, structural or genetic abnormalities) was about 20 percent in euploid fetuses with nuchal translucency above 3 to 3.4 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The absolute risk correlated with nuchal translucency thickness, increasing from 8 to 80 percent with increasing nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/48\">",
"     48",
"    </a>",
"    ]. However, if these fetuses have no abnormalities at second trimester ultrasound screening, the risk of adverse outcome decreases to about 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/41,45,48\">",
"     41,45,48",
"    </a>",
"    ]. This risk is not significantly higher than in the general obstetrical population.",
"   </p>",
"   <p>",
"    A systematic review evaluated 17 studies to determine the prevalence of childhood neurodevelopmental delay in fetuses with increased first-trimester nuchal translucency, normal karyotype, and absence of structural defects or identifiable syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/49\">",
"     49",
"    </a>",
"    ]. The total prevalence of developmental delay in these children was",
"    <span class=\"nowrap\">",
"     28/2458",
"    </span>",
"    (1.4 percent), which is no higher than the rate in the general population. The pooled rate of developmental delay did not significantly differ according to the cut-off used to define increased nuchal translucency (95th centile, 99th centile or 3.0 mm). However, there are several limitations to the available data, including lack of a standard definition of developmental delay, often inadequate methods for ascertainment of cases and developmental assessment, and incomplete identification of syndromes. Additional standardized pediatric evaluations and long-term neurodevelopmental follow-up studies are needed to better define these risks. Some genetic syndromes and conditions associated with developmental delay do not have any features amenable to prenatal diagnosis by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the implications of a cystic hygroma or increased nuchal translucency are the same in a singleton or a multiple gestation. One exception is a multiple pregnancy complicated by monochorionic placentation. As discussed above, in addition to being a marker for aneuploidy and structural malformations, increased and discordant nuchal fluid measurements are associated with the development of twin-to-twin transfusion syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/50\">",
"     50",
"    </a>",
"    ]. The prevalence of increased nuchal translucency in monochorionic pregnancies that develop twin-to-twin transfusion is significantly higher than in those that do not develop this complication (28 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/36\">",
"     36",
"    </a>",
"    ]. When the intertwin nuchal translucency discordance is &gt;20 percent, there is a &gt;30 percent risk of early fetal death or twin-to-twin transfusion syndrome compared to &lt;10 percent when the discordance is &lt;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/37\">",
"     37",
"    </a>",
"    ]. Overall, the likelihood ratio of increased fetal nuchal translucency for the prediction of twin-to-twin transfusion syndrome is 3.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the clinical implications may differ, the initial management of a pregnancy with a cystic hygroma and increased nuchal translucency is the same:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal karyotyping",
"     </li>",
"     <li>",
"      Comprehensive fetal anatomic survey",
"     </li>",
"     <li>",
"      Fetal echocardiography",
"     </li>",
"     <li>",
"      Serial assessment of fetal status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In first trimester Down syndrome screening programs, the risk of Down syndrome is typically calculated using nuchal translucency thickness in combination with maternal analytes and maternal age. Chorionic villus sampling is offered to women with a positive screening result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimum threshold for proceeding to karyotype assessment without maternal analyte screening is unclear. Nuchal translucency thresholds in the range of 3.0 to 4.0 mm have been suggested, given the relatively high risk of Down syndrome at this level [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/22,51,52\">",
"     22,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large observational study found that a threshold of &ge;3 mm would result in 0.4 percent of patients being offered karyotype analysis, with a 1 in 6 chance of detecting aneuploidy, and detection of 19 percent of Down syndrome fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/52\">",
"     52",
"    </a>",
"    ]. On the other hand, a threshold of &ge;4 mm would result in 0.09 percent of patients being offered karyotype analysis, with a 1 in 3 chance of detecting aneuploidy, and detection of 7 percent of Down syndrome fetuses.",
"   </p>",
"   <p>",
"    The authors concluded that immediate invasive testing should be offered for nuchal translucencies at or over 3 mm, given that only 8 percent of patients avoided amniocentesis by awaiting results of analyte testing (ie, first trimester Down syndrome screening result less than 1 in 200). In our practice, we use this same threshold for offering immediate chorionic villus sampling; we also note in their prenatal record that fetal echocardiography should be performed at 18 to 20 weeks of gestation.",
"   </p>",
"   <p>",
"    At a threshold &ge;95th percentile, 5 percent of patients would screen positive and nuchal translucency screening combined with maternal age would detect 60 to 80 percent of fetuses with Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/2,5,20\">",
"     2,5,20",
"    </a>",
"    ]. A threshold &ge;99th percentile would result in 1 percent of patients being offered immediate fetal karyotyping by chorionic villus sampling and would detect 50 percent of Down syndrome fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early fetal anatomic evaluations can be performed using high resolution transvaginal ultrasound; experienced ultrasonographers can detect many major malformations in the first trimester. In addition to a comprehensive anatomic survey, fetal echocardiography is indicated when abnormal first trimester nuchal fluid collections are detected. After excluding aneuploidy, we suggest fetal echocardiography for fetuses with nuchal translucency &ge;2.0 or 3.0 multiples of the median [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/26\">",
"     26",
"    </a>",
"    ]. Specialized centers perform early fetal echocardiography between 13 and 14 weeks of gestation with a complete cardiac evaluation possible in over 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/50/2857/abstract/54\">",
"     54",
"    </a>",
"    ]. However, in the absence of ultrasonographers experienced in first trimester echocardiography, the optimal time for the test is 18 to 20 to 22 weeks.",
"   </p>",
"   <p>",
"    Finally, there is an increased risk of intrauterine and perinatal death in fetuses with increased nuchal edema, particularly if persistent, even after correcting for associated chromosomal and structural abnormalities. There are no studies that specifically address the optimal management of these pregnancies after initial evaluation. Given these risks, we perform serial ultrasound examinations to monitor fetal growth and order antenatal fetal testing in the third trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some nuchal fluid is a normal finding in all first trimester fetuses; however, abnormal accumulations, such as a cystic hygroma or increased nuchal translucency, are associated with an increased risk of chromosomal and structural abnormalities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystic hygroma is a congenital malformation of the lymphatic system resulting from obstruction between the lymphatic and venous pathways in the fetal neck. It may be simple or septated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cystic hygroma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased nuchal translucency refers to measurement of the nuchal fluid space which exceeds the 95th or 99th percentile for gestational age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nuchal translucency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 50 percent of first trimester cystic hygromas occur in fetuses with chromosomal abnormalities, particularly trisomies and Turner syndrome. Increased first trimester nuchal translucency is associated with a 15 percent risk of aneuploidy overall; the risk of aneuploidy increases with increasing nuchal translucency thickness. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Aneuploidy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About one-third of euploid fetuses with first trimester cystic hygromas have major structural anomalies. Structural anomalies are detected in 4 to 10 percent of euploid fetuses with increased nuchal translucency. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Structural anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal karyotyping should be offered to any patient with a first trimester cystic hygroma or significantly increased nuchal translucency, given the relatively high risk of aneuploidy. We use 3.0 mm or the 99th percentile. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal echocardiography at 18 to 20 weeks of gestation is indicated in fetuses with increased nuchal translucency because of the increased incidence of congenital heart disease. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Obstetrical management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some studies have reported an increased prevalence (up to 8.7 percent) of neurodevelopmental delay in children with a fetal history of increased nuchal translucency; however, others have found no excess risk of developmental delay in children with normal karyotype and no congenital malformations in whom first trimester nuchal thickening resolved. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the third trimester, we suggest obtaining serial ultrasound examinations to evaluate fetal growth and antenatal fetal surveillance, given the increased risk of adverse outcomes in affected pregnancies. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/1\">",
"      Podobnik M, Singer Z, Podobnik-Sarkanji S, Buli M. First trimester diagnosis of cystic hygromata using transvaginal ultrasound and cytogenetic evaluation. J Perinat Med 1995; 23:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/2\">",
"      Malone FD, Ball RH, Nyberg DA, et al. First-trimester septated cystic hygroma: prevalence, natural history, and pediatric outcome. Obstet Gynecol 2005; 106:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/3\">",
"      Bekker MN, Haak MC, Rekoert-Hollander M, et al. Increased nuchal translucency and distended jugular lymphatic sacs on first-trimester ultrasound. Ultrasound Obstet Gynecol 2005; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/4\">",
"      Haak MC, van Vugt JM. Pathophysiology of increased nuchal translucency: a review of the literature. Hum Reprod Update 2003; 9:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/5\">",
"      Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005; 29:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/6\">",
"      Bronshtein M, Zimmer EZ, Blazer S. A characteristic cluster of fetal sonographic markers that are predictive of fetal Turner syndrome in early pregnancy. Am J Obstet Gynecol 2003; 188:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/7\">",
"      Haak MC, Twisk JW, Bartelings MM, et al. Ductus venosus flow velocities in relation to the cardiac defects in first-trimester fetuses with enlarged nuchal translucency. Am J Obstet Gynecol 2003; 188:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/8\">",
"      Matias A, Gomes C, Flack N, et al. Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol 1998; 12:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/9\">",
"      Haak MC, Twisk JW, Bartelings MM, et al. First-trimester fetuses with increased nuchal translucency do not show altered intracardiac flow velocities. Ultrasound Obstet Gynecol 2005; 25:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/10\">",
"      Mart&iacute;nez JM, Echevarr&iacute;a M, G&oacute;mez O, et al. Jugular vein and carotid artery blood flow in fetuses with increased nuchal translucency at 10-14 weeks' gestation. Ultrasound Obstet Gynecol 2003; 22:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/11\">",
"      Simpson JM, Sharland GK. Nuchal translucency and congenital heart defects: heart failure or not? Ultrasound Obstet Gynecol 2000; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/12\">",
"      Scott A. Nuchal translucency measurement in first trimester Down syndrome screening. Issues Emerg Health Technol 2007; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/13\">",
"      Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/14\">",
"      D'Alton, ME, Malone, FD, Lambert-Messerlian, G, et al. Maintaining quality assurance for nuchal translucency sonography in a prospective multicenter study: Results from the FASTER trial. Am J Obstet Gynecol 2003; 189:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/15\">",
"      Snijders RJ, Thom EA, Zachary JM, et al. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/16\">",
"      Molina FS, Avgidou K, Kagan KO, et al. Cystic hygromas, nuchal edema, and nuchal translucency at 11-14 weeks of gestation. Obstet Gynecol 2006; 107:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/17\">",
"      Graesslin O, Derniaux E, Alanio E, et al. Characteristics and outcome of fetal cystic hygroma diagnosed in the first trimester. Acta Obstet Gynecol Scand 2007; 86:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/18\">",
"      Rosati P, Guariglia L. Prognostic value of ultrasound findings of fetal cystic hygroma detected in early pregnancy by transvaginal sonography. Ultrasound Obstet Gynecol 2000; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/19\">",
"      Johnson MP, Johnson A, Holzgreve W, et al. First-trimester simple hygroma: cause and outcome. Am J Obstet Gynecol 1993; 168:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/20\">",
"      Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/21\">",
"      Kagan KO, Avgidou K, Molina FS, et al. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 2006; 107:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/22\">",
"      Mangione R, Guyon F, Taine L, et al. Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency. Fetal Diagn Ther 2001; 16:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/23\">",
"      Pandya PP, Kondylios A, Hilbert L, et al. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/24\">",
"      Maymon R, Weinraub Z, Herman A. Pregnancy outcome of euploid fetuses with increased nuchal translucency: how bad is the news? J Perinat Med 2005; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/25\">",
"      Atzei A, Gajewska K, Huggon IC, et al. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 2005; 26:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/26\">",
"      Simpson LL, Malone FD, Bianchi DW, et al. Nuchal translucency and the risk of congenital heart disease. Obstet Gynecol 2007; 109:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/27\">",
"      Lopes LM, Brizot ML, Lopes MA, et al. Structural and functional cardiac abnormalities identified prior to 16 weeks' gestation in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 2003; 22:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/28\">",
"      Ghi T, Huggon IC, Zosmer N, Nicolaides KH. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001; 18:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/29\">",
"      Sananes N, Guigue V, Kohler M, et al. Nuchal translucency and cystic hygroma colli in screening for fetal major congenital heart defects in a series of 12,910 euploid pregnancies. Ultrasound Obstet Gynecol 2010; 35:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/30\">",
"      Sciarrone A, Masturzo B, Botta G, et al. First-trimester fetal heart block and increased nuchal translucency: an indication for early fetal echocardiography. Prenat Diagn 2005; 25:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/31\">",
"      Favre R, Cherif Y, Kohler M, et al. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects. Ultrasound Obstet Gynecol 2003; 21:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/32\">",
"      Maiz N, Plasencia W, Dagklis T, et al. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol 2008; 31:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/33\">",
"      Papatheodorou SI, Evangelou E, Makrydimas G, Ioannidis JP. First-trimester ductus venosus screening for cardiac defects: a meta-analysis. BJOG 2011; 118:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/34\">",
"      Pereira S, Ganapathy R, Syngelaki A, et al. Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol 2011; 117:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/35\">",
"      Sebire NJ, Snijders RJ, Hughes K, et al. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 1996; 103:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/36\">",
"      Sebire NJ, Souka A, Skentou H, et al. Early prediction of severe twin-to-twin transfusion syndrome. Hum Reprod 2000; 15:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/37\">",
"      Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, et al. Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 2007; 29:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/38\">",
"      El Kateb A, Nasr B, Nassar M, et al. First-trimester ultrasound examination and the outcome of monochorionic twin pregnancies. Prenat Diagn 2007; 27:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/39\">",
"      Bilardo CM, Timmerman E, Pajkrt E, van Maarle M. Increased nuchal translucency in euploid fetuses--what should we be telling the parents? Prenat Diagn 2010; 30:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/40\">",
"      Pergament E, Alamillo C, Sak K, Fiddler M. Genetic assessment following increased nuchal translucency and normal karyotype. Prenat Diagn 2011; 31:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/41\">",
"      Souka AP, Von Kaisenberg CS, Hyett JA, et al. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005; 192:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/42\">",
"      Ducarme G, Graesslin O, Alanio E, et al. [Increased nuchal translucency and cystic hygroma in the first trimester: prenatal diagnosis and neonatal outcome]. Gynecol Obstet Fertil 2005; 33:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/43\">",
"      Scholl J, Durfee SM, Russell MA, et al. First-trimester cystic hygroma: relationship of nuchal translucency thickness and outcomes. Obstet Gynecol 2012; 120:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/44\">",
"      Zoppi MA, Ibba RM, Floris M, et al. Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses. BJOG 2003; 110:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/45\">",
"      Souka AP, Krampl E, Bakalis S, et al. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 2001; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/46\">",
"      Souka AP, Snijders RJ, Novakov A, et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998; 11:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/47\">",
"      Van Vugt JM, Tinnemans BW, Van Zalen-Sprock RM. Outcome and early childhood follow-up of chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks' gestation. Ultrasound Obstet Gynecol 1998; 11:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/48\">",
"      Bilardo CM, M&uuml;ller MA, Pajkrt E, et al. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 2007; 30:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/49\">",
"      Sotiriadis A, Papatheodorou S, Makrydimas G. Neurodevelopmental outcome of fetuses with increased nuchal translucency and apparently normal prenatal and/or postnatal assessment: a systematic review. Ultrasound Obstet Gynecol 2012; 39:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/50\">",
"      Cleary-Goldman J, D'Alton ME, Berkowitz RL. Prenatal diagnosis and multiple pregnancy. Semin Perinatol 2005; 29:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/51\">",
"      Chitty LS, Kagan KO, Molina FS, et al. Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study. BMJ 2006; 332:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/52\">",
"      Comstock CH, Malone FD, Ball RH, et al. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening? Am J Obstet Gynecol 2006; 195:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/53\">",
"      Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/50/2857/abstract/54\">",
"      Haak MC, van Vugt JM. Echocardiography in early pregnancy: review of literature. J Ultrasound Med 2003; 22:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 435 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2857=[""].join("\n");
var outline_f2_50_2857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PATHOGENESIS OF NUCHAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis of cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis of nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cystic hygroma or nuchal thickening?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ASSOCIATED ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Structural anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Twin-to-twin transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/435|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/44/6851\" title=\"diagnostic image 1\">",
"      First trim us cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/15/244\" title=\"diagnostic image 2\">",
"      Septated cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/11/4274\" title=\"diagnostic image 3\">",
"      First trimes nuchal lucency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/42/25249\" title=\"diagnostic image 4A\">",
"      Enlarged nuchal translucency2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/55/35696\" title=\"diagnostic image 4B\">",
"      Enlarged nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/17/29979\" title=\"table 1\">",
"      Cystic hygroma outcome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35560?source=related_link\">",
"      Ultrasound diagnosis of neural tube defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_50_2858="Acute eosinophilic pneum High";
var content_f2_50_2858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph of acute eosinophilic pneumonia shows a mixed inflammatory infiltrate expanding the alveolar septa and spilling into adjacent air spaces. The inflammatory infiltrate contains numerous eosinophils and mononuclear cells and is accompanied by a fibrinous exudate resembling hyaline membranes (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumoctes (red arrow) and smaller numbers of cuboidal type II pneumocytes (green arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2858=[""].join("\n");
var outline_f2_50_2858=null;
var title_f2_50_2859="Risks neural blockade";
var content_f2_50_2859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risks associated with neural blockade for pain relief",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Anesthesia of the area innervated by the destroyed nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anesthesia dolorosa (pain superimposed in an area that lacks or has impaired sensation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autonomic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motor paresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder/bowel dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysesthesias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthostatic hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2859=[""].join("\n");
var outline_f2_50_2859=null;
var title_f2_50_2860="Assessment of Rx in HE";
var content_f2_50_2860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods to assess treatment responses in different groups of patients with hepatic encephalopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment endpoint",
"       </td>",
"       <td class=\"subtitle1\">",
"        Assessment of treatment response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Natural history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overt HE",
"       </td>",
"       <td>",
"        Clinical improvement",
"       </td>",
"       <td>",
"        Clinical grading, EEG, SEP",
"       </td>",
"       <td>",
"        Well documented",
"       </td>",
"       <td>",
"        High mortality, precipitating factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic HE",
"       </td>",
"       <td>",
"        Clinical improvement",
"       </td>",
"       <td>",
"        Clinical grading, PSE score",
"       </td>",
"       <td>",
"        Well documented",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-recovery from hepatic coma",
"       </td>",
"       <td>",
"        Recurrence",
"       </td>",
"       <td>",
"        PSE score, MDF (EEG)",
"       </td>",
"       <td>",
"        Depends upon various factors",
"       </td>",
"       <td>",
"        Compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with portacaval shunts (TIPS or surgical)",
"       </td>",
"       <td>",
"        Prevention of HE",
"       </td>",
"       <td>",
"        PSE score, psychometry, MDF (EEG)",
"       </td>",
"       <td>",
"        Well documented",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subclinical HE",
"       </td>",
"       <td>",
"        Electrophysiologic or psychometric parameters",
"       </td>",
"       <td>",
"        Psychometry, MDF (EEG) P300 PHES",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Clinical importance of improvement of certain tests",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEP: somatosensory evoked potentials; PSE: portal-systemic&nbsp;encephalopathy score according to Conn; MDF: mean dominant frequency; P300: event-related acoustic evoked responses; PHES: psychometric hepatic encephalopathy score.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2860=[""].join("\n");
var outline_f2_50_2860=null;
var title_f2_50_2861="Colonoscopy surveillance and screening intervals";
var content_f2_50_2861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    United States Multi-Society Task Force on Colorectal Cancer recommendations for surveillance and screening intervals in individuals with baseline average risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Baseline colonoscopy: most advanced finding(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended surveillance interval (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quality of evidence supporting the recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        New evidence stronger than 2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No polyps",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small (&lt;10 mm) hyperplastic polyps in rectum or sigmoid",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 small (&lt;10 mm) tubular adenomas",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 10 tubular adenomas",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 adenomas",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One or more tubular adenomas &ge;10 mm",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One or more villous adenomas",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoma with HGD",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Serrated lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sessile serrated polyp(s) &lt;10 mm with no dysplasia",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        Low",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Sessile serrated polyp(s) &ge;10 mm",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Sessile serrated polyp with dysplasia",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Traditional serrated adenoma",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        Low",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serrated polyposis syndrome*",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The recommendations assume that the baseline colonoscopy was complete and adequate and that all visible polyps were completely removed.",
"    <div class=\"footnotes\">",
"     HGD: high-grade dysplasia; NA: not applicable.",
"     <br>",
"      * Based on the World Health Organization definition of serrated polyposis syndrome, with one of the following criteria: (1) at least five serrated polyps proximal to sigmoid, with two or more &ge;10 mm; (2) any serrated polyps proximal to sigmoid with family history of serrated polyposis syndrome; and (3) &gt;20 serrated polyps of any size throughout the colon.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143:844. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2861=[""].join("\n");
var outline_f2_50_2861=null;
var title_f2_50_2862="Diastolic BP cardiovascular events HOT trial";
var content_f2_50_2862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diastolic pressure and cardiovascular events in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of major cardiovascular events in relation to achieved mean diastolic blood pressure in the HOT trial. The diastolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hansson, L, Zanchetti, A, Carruthers, SG, et al, Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2862=[""].join("\n");
var outline_f2_50_2862=null;
var title_f2_50_2863="Piggyback method";
var content_f2_50_2863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Techniques for transbronchial penetration: piggyback method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram shows the piggyback method used for tracheobronchial wall penetration in transbronchoscopic needle aspiration. The fiberoptic bronchoscope and needle assembly are moved forward as a unit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_50_2863=[""].join("\n");
var outline_f2_50_2863=null;
